-
Dec 11, 2024 | 
nature.com | Todd P. Knutson |Bin Luo |Michael Morris |Himisha Beltran |Emmanuel S. Antonarakis |Andrew Armstrong | +1 more
AbstractCirculating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors.
-
Nov 21, 2024 | 00405-7&sz=64)
cell.com | David Hsiehchen |Andrew Elliott |Joanne Xiu |Andreas Seeber |Wafik El-Deiry |Emmanuel S. Antonarakis | +12 more
1Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA2Harold C.
-
May 6, 2024 | 
nature.com | Emmanuel S. Antonarakis
AbstractBipolar androgen therapy (BAT) is effective in a subset of metastatic castration-resistant prostate cancer (mCRPC) patients. Treatment selection biomarkers are needed due to other therapies that can be equally efficacious. We performed post-hoc analysis to determine whether baseline serum testosterone (T) is a treatment selection marker in the TRANSFORMER study, a randomized trial of abiraterone-pretreated mCRPC patients assigned to BAT (n = 94) or enzalutamide (n = 101).
-
Apr 19, 2024 | 
nature.com | Neal Shore |Emmanuel S. Antonarakis |Rana R. McKay |Alan Bryce
Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-024-00803-5All authors have requested a correction to include the middle initials for all authors. Neal Shore1,*, Emmanuel Antonarakis2, Ashley Ross3, Catherine Marshall4, Kelly Stratton5, Adanma Ayanambakkam5, Michael Cookson5, Rana McKay6, Alan Bryce7 and Marina Kaymakcalan8should read:Neal D. Shore, MD, FACS^1^, Emmanuel S. Antonarakis, MD 2, Ashley E. Ross, MD, PhD 3, Catherine H. Marshall, MD^4, Kelly L.
-
Apr 3, 2024 | 
onclive.com | Emmanuel S. Antonarakis |Gautam Kumar Jha
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School; and Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital, highlight the significance of collaboration to extend the reach...
-
Mar 29, 2024 | 
onclive.com | Emmanuel S. Antonarakis |Gautam Kumar Jha
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital; and Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School, discuss the practicality and advantages of collaborative efforts...
-
Mar 29, 2024 | 
onclive.com | Emmanuel S. Antonarakis
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School, provides insights into the phase 3 ECLIPSE trial (NCT05204927), detailing how collaboration with community oncologists spurred increased awareness and enrollment for eligible patients with prostate cancer.
-
Mar 20, 2024 | 
onclive.com | Emmanuel S. Antonarakis
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, the Clark Endowed Professor of Medicine, University of Minnesota Medical School, discusses current clinical trials investigating the use of PARP inhibitors that may push the boundaries of the treatment paradigm for metastatic prostate cancer, including studies shifting treatments toward earlier stages of the disease, specifically targeting the hormone-sensitive phase.
-
Dec 15, 2023 | 
urotoday.com | Emmanuel S. Antonarakis |Jacob Orme
Poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA2-mutant cancers are the foremost example of synthetic lethality in prostate cancer. Synthetic lethality is the therapeutic exploitation of a genetic mutation that leads to the death of cancer cells. In BRCA2-altered prostate cancers, the cellular machinery mediating double-strand DNA break repair shifts to rely on PARP enzymes. Thus, PARP inhibitors like olaparib lead to faulty DNA repair and cancer cell death.
-
Dec 12, 2023 | 
urotoday.com | Emmanuel S. Antonarakis
Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today with Dr. Jake Orme, who is a medical oncologist at the Mayo Clinic, and Dr. Emmanuel Antonarakis, who is also a medical oncologist at the University of Minnesota. Thank you both so much for being here with me today. Emmanuel Antonarakis: Thanks, Alicia. Jacob Orme: Thank you. Alicia Morgans: Wonderful.
